Q3 2017
INTERIM RESULTS AS OF SEPTEMBER 30, 2017
This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
RECENT NEWS FLOW
FOR THE THIRD QUARTER 2017 AND UP TO DATE

• J&J $879M deal for HIV and Hepatitis B
  • Equity investment of $33M, bringing total ownership in BN to 5.77%

• PROSPECT Phase 3 study discontinued at third interim analysis
  • Monotherapy in mCRPC futile

• Updated clinical plan for RSV
  • Phase 2 data show durable immune responses at 6 months post vaccination
  • Booster study next, then human challenge trial

• IMVAMUNE freeze-dried contract with BARDA valued at up to $539M
  • Base contract $100M for additional bulk vaccine
  • Contract options of $439M for fill/finish, clinical development, regulatory work, and validation of fill/finish line
  • BN will make $75M investment in fill/finish line over the next years
## FINANCIAL SUMMARY AND OUTLOOK

**On target for the year**

- FY revenue target met; only minor revenues expected in Q4
- PROSTVAC upfront of ~400 mDKK was recognized in Q3 (expected Q4)
- Slightly higher IMVAMUNE revenues than expected
- FY guidance maintained

### Cash preparedness includes cash, cash equivalents, investments in securities and the aggregate amount of undrawn credit lines. USD/DKK = 6.30 (as of September 30, 2017)

<table>
<thead>
<tr>
<th></th>
<th>mDKK</th>
<th>mUSD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9m 2017</td>
<td>9m 2016</td>
</tr>
<tr>
<td>Revenue</td>
<td>1,329</td>
<td>591</td>
</tr>
<tr>
<td>EBIT</td>
<td>531</td>
<td>(82)</td>
</tr>
<tr>
<td>Cash preparedness, period-end</td>
<td>2,808</td>
<td>1,647</td>
</tr>
<tr>
<td></td>
<td></td>
<td>211</td>
</tr>
<tr>
<td></td>
<td></td>
<td>84</td>
</tr>
<tr>
<td></td>
<td></td>
<td>445</td>
</tr>
</tbody>
</table>
## FINANCIAL STATEMENTS

<table>
<thead>
<tr>
<th></th>
<th>9m 2017</th>
<th>9m 2016</th>
<th>FY 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>mDKK</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revenue</td>
<td>1,329</td>
<td>591</td>
<td>1,007</td>
</tr>
<tr>
<td>Production costs</td>
<td>276</td>
<td>192</td>
<td>298</td>
</tr>
<tr>
<td><strong>Gross profit</strong></td>
<td>1,053</td>
<td>399</td>
<td>709</td>
</tr>
<tr>
<td>Research and</td>
<td>373</td>
<td>324</td>
<td>463</td>
</tr>
<tr>
<td>development costs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution and</td>
<td>148</td>
<td>157</td>
<td>213</td>
</tr>
<tr>
<td>administrative costs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total operating</strong></td>
<td>522</td>
<td>481</td>
<td>676</td>
</tr>
<tr>
<td>costs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Income before</td>
<td>531</td>
<td>(82)</td>
<td>33</td>
</tr>
<tr>
<td>interest and taxes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(EBIT)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Financial income/loss</td>
<td>(37)</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Income before</td>
<td>494</td>
<td>(78)</td>
<td>40</td>
</tr>
<tr>
<td>company tax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax</td>
<td>128</td>
<td>(22)</td>
<td>9</td>
</tr>
<tr>
<td><strong>Net profit for the</strong></td>
<td>366</td>
<td>(57)</td>
<td>31</td>
</tr>
<tr>
<td>period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cash preparedness</strong></td>
<td>2,808</td>
<td>1,647</td>
<td>2,292</td>
</tr>
<tr>
<td>(end of period)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

USD/DKK = 6.30
THE STRATEGY

1. Maintain the global leadership of our smallpox vaccine franchise
   - Awarded freeze-dried contract from BARDA
   - Investing in fill/finish line securing future manufacturing requirements

2. Rapidly advance our pipeline of infectious disease programs
   - Completed Phase 2 and outlined development strategy for RSV
   - Expanded collaboration with Janssen on HIV & HBV

3. Establishing a broad and deep cancer immunotherapy franchise
   - Industry and sponsor collaborations for combination studies of CV301 in multiple indications
   - Advancing BN-Brachyury into Phase 2
   - PROSTVAC Phase 3 monotherapy discontinued
   - Initiated two combination studies of PROSTVAC with checkpoint inhibitors from Bristol-Myers Squibb

Strong financial position enables executing on strategy going forward
IMVAMUNE PARTNERSHIP WITH THE U.S. GOVERNMENT

**Freeze-dried**
- Bulk supply: $333m (2015-2019)
- Fill-finish Clinical/Reg & Prod support: $439m (2018 and beyond)
- Additional bulk &/or IMVAMUNE doses
- Approval
- CDC procurement
- 132 million doses
  - US strategic long-term stockpiling goal, as outlined by BARDA.

**Liquid-frozen**
- Positive Phase 3 (POX-MVA-006): 2018
- FDA approval and award of a PRV: 2019
ESTABLISHMENT OF FILL-FINISH CAPACITY

Taking full control of value chain in manufacturing

- BN will invest approx. USD 75 million in a fill-finish line at its existing facility in Denmark
- Contract options of USD 33 million for process transfer and validation of the new manufacturing line
- Secures deliverables for future supply orders and pipeline assets
- Capacity for handling both liquid-frozen and freeze-dried products
OUR COLLABORATION WITH JANSSEN
A LONG-TERM VALUE DRIVER

**MVA-BN Filo (Ebola)**
License & Supply Agreement
US$ 119m

- **2014**
  - Upfront
    - US$ 25m
  - Equity investment
    - US$ 43m

**MVA-BN HPV**
License Agreement
US$ 162m

- **2015**
  - Upfront
    - US$ 9m

**MVA-BN HIV**
License Agreement
US$ 606m

- **2017**
  - Upfront
    - US$ 10m

**MVA-BN HBV**
License Agreement
US$ 230m

- **2017**
  - Equity investment
    - US$ 33m

Potential milestone payments of more than US $1BN + royalties
AT THE FOREFRONT OF RSV VACCINE DEVELOPMENT

Competitive advantages
Designed to mimic natural RSV infection:
- Induction of T-cells and antibodies against RSV
- Induction of mucosal immunity
- Durable immune response lasting an RSV season

Balanced vaccine construct
Encodes 5 distinct targets of RSV to provide protection against multiple antigens providing a balanced T-cell and antibody response

RSV-specific total IgG Antibody Titers

Antibody responses demonstrated over a full RSV season (Phase 2)

Robust T-cell and antibody responses demonstrated in Phase 1 and 2 studies
DEVELOPING A HUMAN CHALLENGE TRIAL FOR RSV
PREPARATION FOR PHASE 3

Strategy
• Collaboration to develop a human challenge model
  • Prior success in development of a flu challenge model
• Healthy volunteers are intranasally infected with a strain of RSV
  • Monitored for viral load, immune markers and clinical symptoms

Key advantages compared to field trials
• Well-defined viral infectivity, independent of RSV season
• Close monitoring of onset, severity and duration of disease symptoms
• Intensive sampling of immune responses
• Rapid, small sample size, cost-effective

Benefits
• Provides important learnings for Phase 3 design
• Mitigates the risk in progressing to large, costly field efficacy trials
• Potential for accelerated approval
MVA-BN RSV
DEVELOPMENT STRATEGY FOR ELDERLY INDICATION

Generate 12 months FU and booster data in ongoing Ph2
Conduct a human challenge trial (HCT)
Agree on Ph3 field efficacy design during EoP2 with FDA
Evaluate HCT topline data in 2018

Initiate Ph3 field efficacy
• Enroll number of subjects needed for futility testing
• Follow-up for symptomatic RSV cases through the 2019/2020 RSV season

Continue Ph3 field efficacy into 2\textsuperscript{nd} season
• Follow-up for symptomatic RSV cases through the 2020/2021 RSV season
CV301
IMMUNOTHERAPY PLATFORM WITH POTENTIAL IN MULTIPLE SOLID TUMORS

Our goal is to become preferred treatment in combination with multiple checkpoint inhibitors (CPI)

- Strong preclinical evidence of combination synergies
- Opportunity to convert the CPI non-responders
- Exploring combinations in company collaborations or with NCI
- Multiple near and long-term data points (ORR, DoR, PFS, OS)

Non-small cell lung cancer (NSCLC)
Proof-of-concept study of CV301 plus KEYTRUDA (pembrolizumab) as first-line maintenance therapy (n=176)

Bladder cancer
Phase 2 single-arm study of CV301 plus TECENTRIQ (atezolizumab) (n=60)

Other potential indications
In addition to NSCLC and bladder, Bavarian Nordic retains all commercial rights in colorectal, pancreatic, breast, ovarian, gastric, liver and renal cancer
COMPLETE TUMOR REGRESSION
FROM POXVIRUS-BASED IMMUNOTHERAPY COMBINED WITH PD-1 & LAG-3 BLOCKADE

CT26-HER2 solid tumor model:
MVA-BN-HER2 immunotherapy (s.c.) and/or anti-PD1 + anti-LAG3 antibody (i.p.)
Q2wks x2 (d1 and 15)

Durable response after mice were re-challenged
MVA-BN BRACHYURY
NOVEL IMMUNOTHERAPY TARGETING THE METASTATIC PROCESS

• Brachyury expression is highly correlated with metastatic disease, and multi-drug resistance

• Brachyury is not expressed in most normal tissue

• Brachyury is responsible for epithelial to mesenchymal transition (EMT), which is a major driver of metastasis

• A Phase 1 study of 38 patients receiving MVA-BN Brachyury showed presence of brachyury specific T-cells in vast majority of patients, post-treatment.

Potential indications:

• Triple negative breast cancer
• Other breast cancer
• Small cell lung cancer
• Neuroendocrine tumors
• Merkel Cell Carcinoma

• Non-small cell lung cancer
• Hepatocellular carcinoma
• Colorectal cancer
• Head and neck/Oral
Transitioning to prime-boost regimen

Phase 1 planned to initiate by end 2017
- Adding fowlpox (FPV) booster to construct
- Safety evaluation expected Q2 2018
- Immune response data Q3 2018
  - Goal demonstrate persistent brachyury-specific T-cell activation with boost

Phase 2 with prime-boost vaccine planned to initiate Q3 2018
- Combination with radiation in advanced chordoma
  - Primary endpoint: Objective response rate (radiation alone <5% ORR at 6 months)
  - Potential for Breakthrough Designation
  - Expect to initiate enrollment Q3 2018
- Combination with PD-1/L1 in various indications planned
<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RSV</strong></td>
<td>Data: booster study</td>
<td>Initiate challenge study</td>
</tr>
<tr>
<td><strong>IMVAMUNE</strong></td>
<td>Top-line data for Phase 3 non-inferiority study</td>
<td>Approval and Priority Review Voucher</td>
</tr>
<tr>
<td><strong>CV301</strong></td>
<td>Phase 1 data of CV301 and OPDIVO</td>
<td>Phase 2 data (ORR) for CV301 and KEYTRUDA</td>
</tr>
<tr>
<td><strong>Brachyury</strong></td>
<td>Data from fowlpox booster study</td>
<td>Initiate study in Chordoma</td>
</tr>
<tr>
<td><strong>PROSTVAC</strong></td>
<td>Emerging data from NCI-sponsored Phase 2</td>
<td></td>
</tr>
</tbody>
</table>
Q&A